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Target Spot for Drugs
Radmila Novakovic
Abstract
Aberrant function or expression of potassium channels can be underlying in 
pathologies such as cardiac arrhythmia, diabetes mellitus, hypertension, preterm 
birth, and various types of cancer. The expression of potassium channels is altered 
in many types of diseases. Also, we have previously shown that natural polyphe-
nols, such as resveratrol, and selective synthetic modulators of potassium channels, 
like pinacidil, can alter their function and lead to the desired outcome. Therefore, 
targeting potassium channels with substance, which has an influence on their func-
tion, is promising access to cancer, diabetes mellitus, preterm birth, or hypertension 
therapy. In this chapter, we could discuss strategies for targeting different types of 
potassium channels as potential targets for synthetic and natural molecules therapy.
Keywords: potassium channels, K channels, modulators of K channels, activators, 
inhibitors, natural polyphenols, resveratrol, K channels antibody
1. Introduction
Ion channels are protein molecules that form pores in the cell membrane and 
membranes of cellular organelles and allow passive flow of ions in the direction of 
their electrochemical gradient and result in electrical currents. Ion channels play 
key roles in membrane potential generation and many cellular activities such as 
signal transduction, neurotransmitter release, muscle contraction, hormone secre-
tion, volume regulation, growth, motility, and apoptosis.
It is widely known that potassium channels (K channels) are transmembrane 
proteins that allow the flow of potassium across the membrane to regulate ion 
homeostasis, cell proliferation, migration, cell volume, and specific processes such 
as muscular contraction.
K channels are the most diverse ion channel type, and each subtype has a specific 
physiological role. K channels are highly attractive as targets for the development of 
novel therapeutics. However, the lack of detailed structural and functional insight 
of K channels and their diversity and ubiquity pose challenges for the development 
of selective drug candidates.
For many years the structure and types of K channels were unknown due to the 
lack of specific ligands for their activation or blocking. A progressive shift in the study 
of these structures has emerged since the discovery of animal toxins that are highly 
specific to individual types but also with the introduction of electrophysiological 
methods—voltage clamp and patch clamp, which have made it possible to test individ-
ual channel. In recent years, many genes detected participate in the encoding of these 
ion channels. Some subtypes are cloned and their biophysical properties determined, 
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but this has not led to a complete elucidation of their function [1]. Especially in recent 
years, studies on this membrane protein family in different tissue types dramatically 
increased. Parallel with this remarkable progress in our understanding of molecular 
diversity, structure, and function, a growing number of discoveries have linked K 
channel gene mutations with various diseases. Such diseases of the heart, kidney, pan-
creas, and central nervous system involve either mutation(s) in the K channel gene(s) 
and/or altered regulation of K channel function. The enhanced understanding of 
these diseases, facilitated by a combination of genomic and biophysical approaches, 
has helped our understanding of how various mutations affect channel function, 
contribute to disease etiology, and rationalize novel treatment strategies.
This review will survey the K channels crucial role in the physiologic and 
pathophysiological function and discuss the emerging understanding of their clini-
cal influence. Once taken into account these strategies, K channels may represent 
suitable and easily accessible different disease biomarkers and targets for therapy.
2. Classification of K channels
Ion channels classified according to the type of ions they conduct, their structure, 
their expression pattern and mode of activation [2]. Potassium channels are com-
posed of complexes of several protein subunits, each encoded by a different gene.
The general model of the K channel is a complex of four α subunits grouped in 
the form of a pore through the membrane. Two transmembrane helices and a short 
loop between them (called the P-loop) are trademarks of these channels. The P-loop 
contains the amino acid sequence of threonine-valine-glycine-tyrosine-glycine, which 
is the selective filter most responsible for the selective passage of K+ ions through the 
channel. This architecture with two transmembrane helices and a loop is an essential 
and universal feature of the K channel, but further, different features characterize each 
channel subfamily. In addition to α subunits, a variety of accessory-regulatory subunits 
such as SUR, β, MinK, and KChiP and others enter the K channel composition [3].
Different types of K channels have been shown to comprise more than 100 differ-
ent protein subunits that are tissue-specific and species-specific [4]. About 75 genes 
coding different types of K channels have detected in human genomes. Molecular 
studies of K channels have allowed their classification based on the primary amino 
acid sequence of the pore-containing subunit. This sequence motif, conserved across 
all K channels, was proposed to correspond to the selectivity filter of the pore-
forming region of the channel protein. There are many (sub)types and isoforms of 
K channels divided into three groups based on transmembrane domains that make 
up the α subunit [1]. These channels are classified into three groups, based on the 
number of transmembrane domains (TMDs) (Figure 1). Within each family, ion 
channels with 65% identical amino acid sequences are further grouped into subfami-
lies [5]. The standard nomenclature for K channels is proposed by the International 
Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and 
Drug Classification (NC-IUPHAR) [6], presented in Figure 1 and Tables 1–4.
Orange is a Kv type with six transmembrane domains, with red main subtypes 
KCa channels; green is a Kir subtype with four transmembrane domains, and blue is 
a subtype with two transmembrane domains K2P.
Understanding the role of K channels and detecting their subunits/proteins in 
different physiological and pathophysiological condition are essential, along with 
linking dysfunction of these channels to specific diseases and disorders. These facts 
speak to the importance of these channels, as a possible therapeutic site for the action 
of drugs that should prevent or stop unwanted conditions/states. Therefore, the 
study of their function and the expression of their proteins are of great importance.
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2.1 Voltage-dependent K channels (Kv) and their modulators
Kv channels are the largest superfamily of the K channel, coding with about 40 genes 
and containing 12 subfamilies, each with several representatives [7]. Representatives of 
Kv1–4, 7, and 10–12 subfamilies can form functional channels as homomers, while Kv5, 
6, 8, and 9 must associate with Kv2 or three subunits to form a functional channel. The 
official nomenclature for Kv channels is Kva.b, where a and b denote the subfamily and 
ordinal number of channel discovery (Figure 1). There are six transmembrane domains 
in each subunit, designated as S1–S6. Four β-subunits are associated with α-subunits and 
located on the cytoplasmic side of the membrane [8]. There is a peptide loop between the 
S5 and S6 domains. Loops of α-subunits face the lumen of the pores and contribute to the 
formation of K+ conductive pores [1]. Domain S4 is the central part of the voltage sensor 
necessary to activate the Kv channel. The opening/closing mechanism also contributes to 
the electrostatic interaction of negative charges on the S2 and S3 domains [9].
The biophysical properties, physiological regulation, and pharmacological prop-
erties of Kv channels are dependent on the combination of α subunits. The combina-
tion on four α subunits may be homo- or heteromultimers [10]. Even more complex to 
these heteromultimers is their interaction with smaller accessory proteins including β 
subunits, KChIP, KchAP, and minK proteins, miRP peptide, and others [11].
The isoforms of Kv channels dominant for smooth muscle are mainly Kv1, Kv2, Kv3, 
and Kv4. For example, in vascular smooth muscle cells, the most important subtypes of 
Kv channels are Kv1 (Kv1.1, Kv1.2, Kv1.3, Kv1.5, Kv1.6), Kv2 (Kv2.1), Kv3 (Kv3.1). Kv4 
(Kv4 .2–3), and Kv7 (Kv7.1–5); in the smooth muscle of the uterus is Kv4 (Kv4.2, Kv4.3). 
The expression pattern depends on the compartment and/or conditions like gravid or 
not in the uterus and part of lent blood vessels. This heteromultimerization seems to 
Figure 1. 
Classification of main types and subtypes of K channels.
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modulate Kv current expression, sensitivity to various substances, as well as biophysical 
properties of channels such as inactivation [12–16]. Further, research shows that the 
most important isoforms for the proliferation, activation, migration, and apoptosis of 
tumor cells are Kv1.3, Kv1.5, Kv2.1, Kv41, Kv9.3, Kv10.1, and Kv11.1 [17].
A recognizable feature of Kv channels is their sensitivity to pharmacologi-
cal modulators. The compounds most commonly used to inhibit Kv channels are 
Table 1. 
Selective modulators of voltage-sensitive channels.
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4-aminopyridine (4-AP) and tetraethylammonium (TEA). In general, Kv channels of 
vascular smooth muscle cells exhibit higher sensitivity to 4-AP, which nonspecifically 
inhibits members of the Kv1–4 subfamilies of these channels [18]. Electrophysiological 
imaging showed that the channels encoded by Kv1.2 and Kv1.5 genes were relatively 
sensitive to 4-AP, while Kv2 channels inhibited TEA more effectively. The 4-AP 
concentrations required for the half-maximal inhibition of Kv channel function varied 
between 0.3 mM and 1.1 mM. These differences in channel sensitivity attribute to the 
different expressions of Kv channel subtypes, the use of different animal species in 
studies, differences in sex, cell isolation techniques, and imaging conditions.
2.1.1  Ca2+- and voltage-dependent K channels (KCa) channels and their 
modulators
Ca2+-sensitive Kv channels other than voltage-dependent depolarizations, for 
opening, also require an increased concentration of Ca2+ ions in the cytoplasm 
[19]. They are divided into channels with high (KCa1-BKCa, maxi K, 100–300 pS), 
intermediate (KCa3-IKCa, 25–100 pS), and low conductivity (KCa2-SKCa, 2–25 pS) 
[20]. KCa1 channels are activated by membrane depolarization and/or Ca
2+ binding 
to the channel; KCa2 and KCa3 channels are voltage-independent and activated by 
Ca2+ binding to calmodulin that constitutively binds to the channels [21].
KCa1.1 channels form of α pore-forming subunits and auxiliary β or γ subunits. 
The four α subunits can build a functional channel on their own. Associated acces-
sory subunits act as potent regulators of most channel characteristics, including 
voltage and Ca2+ sensitivity, as well as sensitivity to pharmacological modulators.
The differences in KCa1.1 channels and Kv channels are the presence of an 
additional transmembrane (S0) segment with the extracellular N-terminus, as well 
as the presence of a long intracellular C-terminus, forming the so-called “channel 
tail.” Furthermore, unlike Kv channels, where the voltage sensor is localizing in the 
S4 domain, the positively charged residues responsible for the voltage dependence 
of the KCa1.1 channels are less centralized and present in the S2, S3, and S4 domains 
[19]. There are different intracellular partners of these channels. Also, KCa1.1 
channels can be the targets of a number of posttranslational modifications such as 
oxidation, glycosylation, and phosphorylation reactions. Finally, the association of 
α subunits with different regulatory subunits further contributes to increasing the 
diversity of these channels [21, 22].
Table 2. 
Selective modulators of Ca2+- and voltage-sensitive channels (KCa).
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Furthermore, four types of β subunits (β1–4) and four types of γ subunits 
(γ1–4) modulate almost all the physiological and pharmacological properties of 
KCa1.1 channels. β subunits contain two, while γ subunits are constructed from a 
single transmembrane domain. The mechanism by which helper subunits interact 
with α subunits and regulate KCa1.1 channel activity is extremely complicated, but 
it is critical for the study and understanding of the vascular disease. In vascular 
smooth muscle cells, the β1 subunit is the predominant isoform, and its dysfunction 
is associated with diabetes, hypertension, and other vascular diseases. Deletion of 
the gene for the β1 subunit causes a significant decrease in Ca2+-sensitivity of the 
channel. As auxiliary subunits of KCa1.1 channels, γ subunits also affect their activ-
ity by modulating voltage and Ca2+-dependence. They play a role in the regulation 
of smooth muscle tone, and change in the gene encoding them leads to a decrease in 
the activity of functional KCa1.1 channels lead to constrictions [23, 24]. Expression 
of β1 subunit can be selectively upstream or downstream-regulated in smooth 
muscle cells, without reflecting to α subunit expression. Occurs under the influ-
ence of various physiological and pathophysiological conditions, as well as during 
hormonal stimulation and that increase or decrease the channel activity [24, 25].
KCa1.1 channels also represent important targets in the mechanism of action of 
various activators or inhibitors. Adenosine and β-adrenergic agonists activate KCa1.1 
channels via cAMP-dependent and cGMP-dependent pathways. Especially in vascu-
lar smooth muscle cells, elevated levels of cGMP and activation of PKG with NO 
result in the phosphorylation of BKCa and their subsequent activation. On the other 
hand, angiotensin II and endothelin-1 inhibit KCa1.1 channels in coronary arteries 
by PKC-independent mechanisms [26].
The pharmacology of KCa1.1 channels spread from nonspecific blockade with 
TEA and alkaloids, like paxillin, to more effective specific inhibitors scorpion tox-
ins, such as iberiotoxin and charybdotoxin. Although these compounds do not have 
pure therapeutic potential, they are very useful tools for studying the function of 
these channels. Several small-molecule KCa1.1 channel openers have been detected 
for both native and cloned channels. For example, benzimidazole NS-1619 activates 
KCa1.1 channels, but its functional effects also include inhibition of Ca
2+ currents 
and Kv channels [20]. And many other substances can modulate the activity of 
KCa1.1 channels. Estrogen binds at a high micromolar concentration to the KCa1.1 
channel, primarily to the β1 subunit, and directly regulates channel expression as 
well as its function. Heme proteins and reactive oxygen species are proven modula-
tors of these channels since both inhibit their activity in vascular smooth muscle 
cells by acting on the α subunit. Ethanol also inhibits KCa1.1 activity in vascular 
smooth muscle cells causing vasoconstriction to increase [27].
KCa2.1, KCa2.2, and KCa3.1 channels are mostly present in neurons, endothelium 
of the blood vessels, epithelium, and in several types of smooth muscle, e.g., in the 
urinary tract. Thus, the opening of these channels is independent of the membrane 
potential but strictly dependent on Ca2+. Complex Ca2+ calmodulin induces a 
conformational change leading to the opening of the pore [28].
Pharmacologically, KCa2 channels are highly sensitive to bee venom and apamin 
with different affinity for all channel isoforms: KCa2 channels are the most sensitive 
and KCa1 the least. Scilatoxin, biculculin, dequalinium, and its more potent derivative 
UCL1684 are also potent inhibitors of these channels group. The compounds, such as 
clotrimazole and TRAM-34, are more specific inhibitors of KCa3.1 channel. KCa3.1 cur-
rent can be reduced by the scorpion toxin charybdotoxin, like KCa1.1 channels. Both 
types of channels are activated by chlorzoxazone, zoxazolamine, riluzole, 1-EBIO, 
its more potent DC-EBIO derivative, and NS-309. However, these compounds are 
not successful, such as Ca2+ for channel activation. Moreover, an increase in channel 
sensitivity for Ca2+ is an assumed mechanism of their action [29].
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2.2 Inwardly rectifying K channels (Kir) and their modulators
The inwardly rectifying (Kir) channels conduct K+ ions into the cell at a mem-
brane potential more negative than the equilibrium potential for K+, while at more 
positive potentials, the output K+ current is limited and barely detectable [30]. The 
explanation for the phenomenon of inward rectification is in the fact that intracel-
lular Mg2+ and polyamines (spermine and spermidine) block output K+ currents. 
As carriers of positive charge, polyamines and Mg2+ interact with the negatively 
charged amino acids present in the transmembrane M1 domain and terminal 
C-terminus of the Kir channel, thereby inhibiting the passage of K+ ions through 
the pore [31]. Kir channels have been identified in many types of cells. Seven 
subfamilies are identified so far (Figure 1 and Table 3).
Structure of Kir channel is consisting of four α subunit-forming subunits, 
each containing two transmembrane domains (M1 and M2) and a P-loop 
Table 3. 
Selective modulators of inwardly rectifying K channels (Kir).
9Potassium Channels as a Potential Target Spot for Drugs
DOI: http://dx.doi.org/10.5772/intechopen.92176
between them. The properties and functions of Kir channels vary between 
different tissues and species. For example, Kir channel expression is most 
pronounced in the smooth muscle of the autoregulatory vascular compartments, 
such as the coronary and cerebral circulation. Kir duct expression increases with 
decreased blood vessel diameter. The difference in expressive Kir channels can 
be explained by the fact that the conduction artery shows a very small response 
to a smaller version of extracellular K, whereas resistant arteries show a positive 
response [32].
ATP-sensitive Kir channels (KATP) are the exceptions, which have a more 
complex heterooctamer structure with multiple types of accessory subunits  
[1, 3]. Structurally, KATP channels form of four pore-forming Kir6.x subunits 
and four regulatory subunits known as sulfonylurea receptors, SURx. Kir6.x 
subunits are responsible for ATP inhibition and SURx for nucleoside-diphos-
phate activation.
Functional expression of the KATP channel requires coexpression of Kir6.x and 
SURx subunits in a 1:1 ratio. SUR1 is predominantly present in pancreatic β cells. 
SUR2 has two variants, SUR2A and SUR2B, which are generated by alternative 
excision of exon 38 in the ABCC9 gene. SUR2A is mainly present in the myocar-
dium and skeletal muscle, while SUR2B generally is distributed in the vascular and 
myometrial smooth muscle cells [15, 23, 32, 33].
Numerous studies have highlighted that KATP channels in vascular smooth 
muscle cells play an important role in achieving systemic vasodilation during 
hypoxia, increasing blood flow to the heart, kidney, and muscle. This vasodila-
tion is attributed to the release of NO or adenosine due to hypoxia but also to the 
direct effect of hypoxia itself. During hypoxia, KATP channels may be activated by 
a decrease in ATP, a decrease in pH and partial pressure of oxygen, or an increase 
in intracellular lactates and ADP. These factors can activate KATP channels directly 
and/or potentiate NO activation [34].
KATP channels play their roles in the mechanism of the action of relaxation 
and contraction by interacting with various protein kinases. Thus, KATP channels 
activated by protein kinase A (PKA) and cGMP-dependent protein kinase par-
ticipate in the mechanism of action of endogenous vasodilators such as adenosine 
and prostacyclin. On the other hand, activation of protein kinase C (PKC) and 
vasoconstrictor-induced increases in intracellular Ca2+ caused by noradrenaline, 
vasopressin, endothelin, and angiotensin II were accompanied by inhibition of the 
KATP channel [35, 36].
KATP channels in the smooth muscle are inhibited by antidiabetics from a group 
of sulfonylurea derivatives, such as glibenclamide and tolbutamide. Glibenclamide 
is the most commonly used KATP channel inhibitor in vascular smooth muscle stud-
ies, whereas tolbutamide shows much lower potency [11, 37].
In the study of potential drugs, the core interest is directed towards KATP chan-
nels, since they exhibit activity under basic conditions and significantly contribute 
to the control of the resting membrane potential [38].
2.3 K channels with two pores (K2P) and their modulators
K2P channel subunit consists of two regions that participate in pore forma-
tion (P1 and P2, hence their name) and four transmembrane domains (M1–
M4). Functional channels form as dimers of these subunits that form a single 
pore selectively permeable to potassium [39]. Activity of these channels is 
voltage-independent, and they under physiological conditions (high concentra-
tion of K+ in the cytoplasm and low extracellular) conduct K+ ions from the cell 
into the extracellular space [40], leading to stability of the resting membrane 
Molecular Pharmacology
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potential. K2P channel activity is regulated by a wide variety of factors such 
as pH, stretching of membrane, temperature, and endogenic compounds like 
arachidonic acid. K2P channels play important roles in many physiological 
processes: neuroprotection, cerebrovascular vasodilation, regulation of aldo-
sterone production and secretion, depression, chemoreception, and pulmonary 
vasoconstriction [41].
The neuroprotective agent riluzole, currently in use for the treatment of amyo-
trophic lateral sclerosis, has been shown to be an activator of TREK-1 and TRAAK 
channels. Volatile general anesthetics such as chloroform and isoflurane have also 
been shown to target TREK-1 channels [1].
Table 4. 
Selective modulators of K channels with two pores K2P.
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3.  Natural polyphenols and antibody for K channels a promise for future 
cancer treatment
3.1 Natural polyphenols
Natural polyphenols are secondary metabolism of plants that have multiple 
activities in determining plant properties such as color, aroma, taste, solution, 
pathogen resistance, etc. Natural polyphenols have been expanding in the interest of 
both the scientific community and the public over the past decade when they have 
shown to have a significant function in the prevention of cancer, cardiovascular 
disease, diabetes and neurodegenerative disorders, etc. [42–45]. Polyphenols are the 
most common antioxidant constituents, and their source is various foods of plant 
origin: fruits, vegetables, seeds, especially nuts, chocolate, wine, tea, and coffee.
Research carried out during the last decade provided evidence that natural, 
biologically active polyphenols, such as resveratrol, genistein, quercetin, and 
catechin-gallate, and curcumin have a wide spectrum of pharmacologic properties 
such as anti-inflammatory, antioxidant, anticarcinogenic, antiaging, neuroprotec-
tive, and cardioprotective effect. Resveratrol, stilbene from grape and red wine, 
genistein, isoflavone from soy-based food, and catechin-gallate from tea influence 
cancer initiation, promotion, and progression through diverse signal-transduction 
pathways that control cell growth and division, inflammation, apoptosis, metasta-
sis, and angiogenesis [46].
Many studies suggested that Kv channels could be the targets of polyphenols, 
directly and indirectly [15, 43, 47]. Furthermore, there is evidence that modulation 
of Kv channels via the PI3K/Akt/mTOR pathway may be a possible indirect mode 
of action of polyphenols [48, 49]. The PI3K/Akt/mTOR pathway is known to play 
an important role in cell survival (inhibition of apoptosis), proliferation, and cell 
metabolism, and PI3K activity has been linked to a variety of human cancers [50]. 
As described above, the effect on the kinase pathway would result in the modulation 
of K channel function.
Polyphenols are thought to have several different mechanisms that prevent 
cardiovascular disease. The following effects are reported in the literature: antioxi-
dant, anti-aggregation, beneficial effects on plasma HDL-cholesterol levels (raising 
HDL-cholesterol levels), inhibition of LDL-cholesterol oxidation, improvement 
of endothelial function, and stabilization of atherosclerotic plaque [51]. The 
mechanism of the vasodilatory action of polyphenols is not fully understood. Still, 
there are many results that polyphenols included K channels in their mechanism of 
action [42–44]. It is shown that these molecules can cause endothelium-dependent 
and endothelium-independent relaxation of the blood vessel. Polyphenols are 
known to modulate many intracellular signaling pathways as well as the expres-
sion of individual genes. Thus, plant polyphenols have been described to activate 
endothelial NO synthase (eNOS), increase nitric oxide production, and thus induce 
endothelium-dependent vasodilation. Activation of eNOS occurs due to an increase 
in the intracellular level of Ca2+ ions and phosphorylation of PI3 kinase.
Previous reports indicated that resveratrol inhibits vasocontractile response and 
relaxes different arteries and vein by the activation of smooth muscle Kv and KCa1.1 
channels [43, 44]. But, data from electrophysiological studies suggest that resvera-
trol inhibits L-type Ca2+ channels and enhances activity of the KATP channels in rat 
hearts [47].
Additionally, it has been shown that the K channel family affects cell function 
and plays a significant role in regulating myometrium contractility [3, 17]. Changes 
in the expression or activity of K channels can translate into inadequate repolariza-
tion leading to aberrant uterine activity. Thus, K channel alterations may contribute 
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to certain pathophysiological conditions such as preterm labor. Many studies have 
shown that opening of different types of K channels leads to the relaxation of non-
pregnant as well as pregnant myometrium [3, 15, 17, 24, 52]. It seems that function 
and molecular expression of K channels are dependent of stages of pregnancy, the 
age, and of hormones influences [15, 53]. K channels, as a novel target to prevent 
preterm delivery with nontoxic natural polyphenols, are the important work in 
addressing the need for innovative tocolytic therapeutics.
In such a scenario, combination treatment with K channel modulators and 
natural polyphenols could be beneficial for cardiovascular, renal, or gynecologic 
disorders.
3.2 Antibodies
The increasing knowledge on the expression of K channels in tumors, together 
with the information on the structure and function of these molecules and the 
possibility of detailed in vitro and in vivo studies, makes this family of channels 
an attractive candidate for the design of personalized therapies for oncological 
diseases.
As already stated, in addition to regulating many physiological functions, K 
channels are aberrantly expressed in different types of tumors. In cancer cells, 
K channel activity regulates cell proliferation, resistance to apoptotic cell death, 
tumor angiogenesis, invasiveness, and metastatic spread. Moreover, being 
expressed in cells of the tumor microenvironment, K channels can also modulate 
the immune/inflammatory response, which contributes to the drive of cancer estab-
lishment and progression [16, 54]. After many years of studies, some K channels are 
emerging as novel cancer biomarkers, to be employed to stratify patients for either 
prognostic or predictive purposes [55].
Although the attempts to generate blocking monoclonal antibodies using con-
ventional approaches have shown limited success, the insight that structural studies 
have provided in the last few years makes it possible to design alternative strategies 
with higher chances of success. This opens doors for a new approach to combine the 
advantageous features of K channels-specific antibodies and their modulators and 
will undoubtedly result in improved therapy alternatives in the near future.
It anticipates that a detailed understanding of structural aspects would revolu-
tionize and refine approaches targeting K channels for therapeutic purposes.
4. Conclusion
K channels are crucial for all aspects of life by regulating the excitability of 
neurons and the heart, contracting muscles, secreting hormones, moving fluid, and 
activating the immune cell. K channel modulation accordingly offers tremendous 
opportunities for drug development. However, with 7% of clinically used drugs 
targeting ligand-ion channels and only 5% of voltage-gated channels targeted, 
ion channels are currently “underrepresented” drugs in clinical practice [56]. The 
reason for this discrepancy is the fact that K channels belonging to a single subtype 
can be found in the different tissues, e.g., the heart and brain, where they play 
different roles in the nervous excitability and contractility of the heart muscle. It 
was mentioned above that even within the same tissue there are subtypes of chan-
nels that potentially play different roles in disease and physiology, thus making 
sub-selective modulators of each subtype of K channels desirable as candidates for 
drug development. The ubiquity of K channels makes it important to develop highly 
selective agents. Furthermore, numerous studies have shown that different diseases 
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as diabetes mellitus and hypertension cause changes in K channel expression and 
function that further complicate solution innovative sub-selective therapeutics or 
antibodies. However, it is not remote the time in which it will be possible to target 
specific K channels for therapeutic purposes.
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